melanoma treatment

Tc99m Tilmanocept Study for Cancer Australia
Tc99m Tilmanocept Study for Cancer Australia

Tc99m Tilmanocept Study for Cancer Australia

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the publication of a manuscript titled "Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer," based on work performed at the Crown…

read more
474 315 HL Pharma
Enter your search term...